In ovarian cancer, p53/p21pathway mediates antiproliferative action of cisplatin, but simultaneously cisplatin induces a p53-associated cellular protein involved in the cisplatin resistance (Yang et al., 2019). Here, TP53 is linked to ovarian carcinoma.